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Catheter ablation is the cornerstone of the rhythm control treatment of atrial 
fibrillation (AF). During this procedure, creating a contiguous and durable lesion 
set is essential to achieve good long-term results. Radiofrequency lesions are created 
in two phases: resistive and conductive heating. The ablation catheters and the gen-
erators have undergone impressive technical developments to enable homogenous 
and good-quality lesion creation. Despite recent years’ achievements, the durable 
isolation of the pulmonary veins remains a challenge. These days, intensive research 
aims to evaluate the role of high-power radiofrequency applications in the treat-
ment of patients with cardiac arrhythmias. The use of high-power, short-duration 
applications might result in a uniform, transmural lesion set. It is associated with 
shorter procedure time, shorter left atrial, and fluoroscopy time than low-power 
ablation. This technique was also associated with a better clinical outcome, possibly 
due to the better durability of lesions. Multiple clinical studies have proven the 
safety and efficacy of high-power, short-duration PVI.
Keywords: catheter ablation, high power, short duration, lesion formation, atrial 
fibrillation
1. Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. AF is 
associated with a higher risk of mortality, and it is one of the major causes of stroke, 
heart failure, sudden death, and cardiovascular morbidity worldwide [1, 2]. Thus, 
appropriate management of this arrhythmia and underlying diseases is essential.
Catheter ablation is the cornerstone of the rhythm control treatment of AF by 
isolating the pulmonary veins from the left atrium (pulmonary vein isolation; PVI). 
During this procedure, creating a contiguous and durable lesion set is essential to 
achieve good long-term results [3, 4]. When applying radiofrequency (RF) abla-
tions, the lesions are created in two phases: resistive and conductive heating of the 
myocardial tissue [5]. Both the ablation catheters and the generators have undergone 
impressive technical developments to reach homogenous and good-quality lesion 
creation. Despite recent years’ technological developments, the durable isolation of 
the pulmonary veins remains a challenge. Moreover, procedural complications also 
remained a significant issue [6–8].
Nowadays, the use of high-power (HP) radiofrequency applications is in the 
center of scientific research. High-power, short-duration (HPSD) ablation might 
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result in a more uniform, transmural lesion set [9]. Thus, it can reduce procedure 
time and seems to be non-inferior compared to low-power (LP) ablation. This 
technique was associated with a better clinical outcome, possibly due to the better 
durability of PVI [10]. Multiple clinical studies have proven the safety and efficacy 
of high-power, short-duration PVI for AF ablation.
In this chapter, we will introduce the theoretical background of HPSD ablation, 
and we also aim to discuss the main differences with low-power ablations, also 
mentioning some relevant clinical trials.
2. Theoretical background of radiofrequency lesion formation
Radiofrequency catheter ablation is the first-line treatment choice for most 
symptomatic arrhythmias. The tissue injury caused by this energy source is ther-
mally mediated, resulting in discrete and homogeneous lesions.
2.1 Radiofrequency energy delivery and tissue heating
The standard RF generator used for catheter ablation produces a sine wave alter-
nating current at 350–500 kHz. The RF energy delivery is usually unipolar between 
the ablation catheter’s tip electrode and a large surface indifferent electrode applied 
to the patient’s skin. During RF energy delivery, the alternating electrical current 
traverses from the ablation catheter’s tip electrode through the intervening tissue 
to the indifferent electrode. The passage of the electric current through the tis-
sue results in electromagnetic heating, termed resistive heating. Resistive heating 
is proportional to the square of the current density; current density is inversely 
proportional to the square of the distance from the ablation electrode. Therefore, 
power dissipation per unit volume decreases dramatically with the distance, and 
resistive heating decreases with the distance from the ablation electrode to the 
fourth power. Since the region of the highest current density is at the tissue below 
the ablation electrode, resistive heating of the tissue only occurs in a thin layer 
within a very close vicinity to the ablation electrode. Deeper tissue heating occurs as 
a result of passive heat conduction from this narrow resistive heating zone, termed 
conductive heating (Figure 1). Temperatures above 50°C are required for irrevers-
ible myocardial injury. Of note, a non-negligible part of the delivered energy will 
be lost as a consequence of convective heat loss to the blood pool surrounding the 
ablation electrode [5].
2.2 Factors influencing radiofrequency lesion creation
Lesion formation is dependent on optimal electrode-tissue contact force (CF), 
RF power, size of ablation catheter tip electrode, and the duration of RF delivery.
The role of the ablation catheter tip size will not be discussed in this chapter, 
as the vast majority of the electrophysiology laboratories only use 3.5–4-mm tip 
electrodes in everyday practice, and large-tip electrodes are utilized less commonly.
Lesion size is directly proportional to the electrode-tissue contact temperature. 
Therefore, those factors that increase the temperature at the electrode-tissue inter-
face (e.g., RF power and contact force) will also increase the lesion size.
It is known that the lesion size is proportional to RF power, as a higher RF power 
results in a larger current density at the ablation electrode leading to greater tissue 
heating. However, the deliverable power (and time) might be limited by an imped-
ance rise that occurs when the temperature at the electrode-tissue interface reaches 
100°C. This impedance rise can be prevented by maintaining the electrode-tissue 
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interface temperature below 100°C by cooling the tip of the ablation catheter. A 
landmark in vivo study was presented by Nakagawa et al. [11]. They evaluated the 
role of presence or absence of catheter tip irrigation in eleven anesthetized dogs’ 
tight muscles. They executed temperature measurements on the catheter-tissue 
surface and tissue temperatures in 3.5 mm and 7 mm depth. The main findings were 
that in the case of applications with irrigation of the catheter tip, electrode and 
electrode-tissue interface temperatures were consistently lower than the tissue tem-
perature at 3.5 mm depth. Moreover, lesion sizes were larger in the case of irrigated 
ablations, most likely because they could deliver higher-power applications in this 
group [11, 12].
Later, studies concluded that irrigation minimally affects lesion size by cooling 
the tissue surface (when the applied power is the same). Larger lesions may only 
be created with the use of irrigation by making the delivery of higher-power levels 
possible. This is especially important in case of low blood flow areas where high 
temperatures are reached at relatively low-power levels, resulting in insufficient 
lesion formation. In such areas, irrigation decreases temperature during ablation 
and therefore makes the delivery of a higher power possible [13].
When tissue contact is poor, a larger surface area of the ablation electrode is 
exposed to the circulating blood pool, which results in less-efficient tissue heating. 
Conversely, good tissue contact results in a larger area where catheter touches the 
tissue and less amount of current will be lost to the blood pool. In case of low CF, a 
higher power might be necessary to reach an optimal degree of tissue heating. On 
the other hand, similarly, good lesion formation can be produced even with smaller 
CF in case of high-power applications [5]. A few years ago, contact force-sensing 
ablation catheters were introduced and nowadays, their use is a part of everyday 
practice. They allow to reach better durability of lesions and thus facilitate the 
procedure in terms of achieving better safety and efficacy [3, 14–16].
Finally, an essential determinant of lesion size is the duration of RF applica-
tion. The rate of tissue heating at the electrode-tissue contact point is rapid, and 
steady-state temperatures are reached within a few seconds in the resistive heating 
zone. Conversely, deeper tissue sites have a much slower rate of temperature rise 
due to the time required for conductive heating. Thus, the lesion growth is rapid in 
the first few seconds but much slower thereafter. Studies have demonstrated that 
the half-time of lesion growth is approximately 7–10 s, and maximum lesion size is 
achieved after 30–40 s of RF energy delivery [5].
Figure 1. 
Phases of lesion formation during radiofrequency ablation. The first phase is the resistive heating occurring in 
a thin layer of the tissue contacting the ablation electrode. The second phase is the heat conduction from the 
resistively heated zone to the more distant tissue layers (conductive heating).
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3. Experimental studies on HPSD ablation
In case of conventional, low-power RF applications, most of the thermal injury 
is a result of heat conduction from the resistively heated thin surface layer. On the 
other hand, lesion size could be increased by producing direct resistive heating 
deeper in the tissue by applying higher RF power. The use of a high-power level is 
allowed by irrigation of the ablation electrode with saline. Saline irrigation main-
tains a low electrode-tissue interface temperature during radiofrequency applica-
tion at high power, which prevents a rapid temperature and impedance rise.
Nakagawa et al. found that by applying higher power with an irrigated catheter, 
a higher temperature can be measured at 3.5 mm tissue depth than at the electrode-
tissue interface, which indicates that direct resistive heating occurred deeper in the 
tissue (rather than by conduction of heat from the surface) [11]. Other early studies 
also found that high-power ablations are effective; however, there was a concern 
regarding the safety of the procedures based on the animal study results [17]. This 
seems justified since high-power ablations necessitate reliable real-time feedback 
on lesion formation to avoid serious complications. Lesion-predicting parameters 
were not available before the contact force era; therefore, research interest regard-
ing high-power RF ablation decreased transiently. However, after introducing 
CF-sensing catheters and lesion-predicting parameters, the topic became interest-
ing again. If high power is applied for a long duration, it leads to a big resistive heat-
ing zone to which a large conductive heating zone is added, resulting in the creation 
of extensive lesions. Therefore, high-power ablations should only be applied for a 
short time to avoid the injury of extracardiac structures.
Nowadays, intensive research is going on examining high-power, short-duration 
RF ablation technology. Bourier et al. [9] showed that HPSD ablation results in a 
different lesion geometry (e.g., larger diameters but smaller depth) compared to 
conventional lower-power ablation. Still, the depth of the high-power applications 
seems sufficient to reach transmural lesions in the atria (Figure 2). Moreover, the 
larger diameters might improve the chance of creating a contiguous lesion set [9].
Two other preclinical studies evaluated the efficacy and safety of very high-power, 
short-duration RF ablation (90-W power applied for 4 s) compared to low-power, 
long-duration ablation in swine models. Both studies showed that HPSD ablation 
results in improved lesion continuity, lesion transmurality, and shorter ablation time, 
while the safety profile is comparable to conventional low-power ablation [10, 18].
Figure 2. 
Properties of lesions created by high-power, short-duration and low-power, long-duration radiofrequency 
ablation. The high-power, short-duration ablation (panel A) results in a different lesion geometry (e.g., larger 
diameters but smaller depth) compared to conventional lower-power ablation (panel B). Still, the depth of the 
high-power application’s lesion seems sufficient to reach transmurality in the atria.
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4. Clinical trials evaluating HPSD PVI
4.1 Ablation index-guided PVI with HPSD applications
According to previous studies, ablation index (AI) is a valuable marker of lesion 
creation during PVI procedure, minimizing the risk of AF recurrence after ablation 
[14, 19]. AI is calculated by a weighted formula including CF, RF time, and power 
so that a higher-power application can reach target AI with a shorter duration and 
even with high energy, RF applications’ lesion creation can be monitored in real 
time properly. Of note, the AI is validated up to 45 W; thus, lesion creation can be 
reliably monitored with AI at a maximal power of 45 W. The decrease of RF time 
per application theoretically makes the maintenance of a stable catheter position at 
the given site easier, resulting in a better lesion quality. It is well known that HPSD 
ablation results in a different lesion geometry (e.g., larger diameters but smaller 
depth) compared to conventional lower-power ablation. Still, the depth of the HP 
applications is sufficient to reach transmural lesions in the atria. The power used for 
ablation can be varied based on the operating physician’s decision. As we will show 
in this subchapter, 45–50 W was used in the majority of trials.
The use of high-power (HP) RF applications can reduce procedural time and 
seemed to be non-inferior to low-power (LP) ablation in a multicenter study [20]. 
Vassallo et al. investigated patients who underwent AF ablation with HP (50 W on 
the anterior wall and 45 W elsewhere in the left atrium) or LP (30 W) RF ablation 
power settings. HPSD was safe and efficient compared with LP ablation and was 
associated with a reduced procedural time and total RF time. They also concluded 
that HPSD might reduce the chance of esophageal injury and it may also reduce 
the recurrence of atrial tachyarrythmias [21]. The PVI procedure time was also 
decreased significantly with HP (50 W) ablation compared to conventional LP 
(30 W) ablation settings in a study published by Bunch et al. [22].
We would like to highlight a prospective randomized trial conducted by 
Wielandts et al. [23]. They randomized 96 AF patients to HPSD (45 W) or LPLD 
(35 W), CLOSE protocol-guided PVI and found that fluoroscopy dose and RF time 
are lower in case of HPSD ablation. There was no difference in terms of six-month 
AF-free survival between the two groups. On the other hand, postprocedural 
endoscopic evaluation of esophageal lesions drew attention to a narrower safety 
margin at the posterior wall using high power, especially when applying higher CF 
and reaching higher AI values [23].
Finally, we would like to mention a recent meta-analysis of 15 studies evaluating 
PVI with HPSD versus LP ablation technique. Overall, data of 3718 patients were 
included in the analysis. The main result is that freedom from atrial arrhythmias 
was higher in case of HPSD RF ablation when compared with conventional LP 
RF ablation. Acute PV reconnection was lower and first-pass isolation was higher 
with HPSD. There was no statistically significant difference in total complications 
between the two groups. Total procedure duration, fluoroscopy duration, and RF 
ablation time were all significantly lower in HPSD ablation [24].
4.2 HPSD safety endpoints: esophageal lesions
Esophageal lesions are not rare after RF point-by-point PVI, even with the 
use of CF sensing catheters [25, 26]. A rare but potentially lethal complication of 
pulmonary vein isolation is atrio-esophageal fistula [6]. Thus, besides improving 
efficacy, reducing the possibility of causing esophageal lesions should be the main 
goal of technological developments. High-power RF applications have a larger resis-
tive heating zone, but conductive heating does not significantly affect the lesion 
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creation if the application is kept short. On the other hand, one has to keep in mind 
that applying high power for a longer duration can cause extensive tissue injury 
damaging peri-cardiac structures such as the lung or the esophagus.
A study involving 85 patients who underwent PVI with 35-W power using 
CF-sensing catheters and AI guidance showed that the occurrence of esophageal 
injury after PVI is markedly low (1.2%), even in those cases where an intraesopha-
geal temperature rise was detected during the procedure. They concluded that 
their strategy of delivering contiguous, relatively high-power, and short-duration 
radiofrequency applications is safe even at the posterior wall [27]. Two other larger 
trials involving 355 and 271 patients who underwent AI-guided PVI with 45–50-W 
power also concluded that HPSD technique is relatively safe. Esophageal lesions 
had a similar incidence in HPSD group as in the low-power group, and there was 
a low incidence of esophageal temperature elevation in the HPSD group [28]. 
They concluded that HPSD might even have a protective effect avoiding incidental 
esophageal injury due to the smaller lesion depth [29]. Of note, this is only true 
if high-power applications are kept very short on the posterior wall, but longer-
duration ablations might lead to severe complications.
5. Very high-power, short-duration ablation of AF
The impressive safety and efficacy profile of high-power, short-duration 
PVI procedures performed with 45–50 W formed a claim to even higher-power 
ablations with the potential promise of making procedures even shorter while 
maintaining safety and efficacy. For sure, ablations with very high power should be 
carried out with caution to avoid the use of high CF values. Appropriate irrigation 
is also essential to use this technology, which is solved at the recent version of the 
CoolFlow (Biosense Webster) pump used for 90-W ablations with the QDOT Micro 
(Biosense Webster) catheter. Because of the very short time of the applications, 
lesion-predicting parameters such as AI do not work for this type of ablation. Visual 
tags of the ablated area are located at the spot where the application was started 
(Figure 3).
Long-term results of such clinical trials are likely to be published in the near 
future. Here, we would like to mention two studies dealing with very high-power, 
short-duration PVI.
Figure 3. 
Electroanatomical map of a successful pulmonary vein isolation performed with very high-power, short-
duration ablation technique. All ablation tags represent single applications with 90-W power for 4 s.
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Kottmaier et al. [30] compared PVI procedures performed with 70 W versus 
30–40 W. Very high-power applications were terminated at 5 and 7 s on the pos-
terior and anterior walls, respectively. HPSD ablation demonstrated a comparable 
safety profile to conventional ablation. Moreover, HPSD ablation led to significantly 
fewer arrhythmia recurrences after the one-year, follow-up period. Of course, 
RF time and procedural time were also significantly shortened by the use of 
HPSD [30].
A prospective, multicenter, single-arm study was published by Reddy et al. [31], 
aiming to evaluate the safety and efficacy of very HPSD pulmonary vein isolation 
with 90 W. All applications were terminated after 4 s. They demonstrated the clini-
cal feasibility and safety of very high-power, short-duration ablation, with very low 
procedure and fluoroscopy times [31].
6. Conclusions
Pulmonary vein isolation is the cornerstone of rhythm-control therapy for 
atrial fibrillation. A few years ago, new technologies such as contact force-sensing 
ablation catheters were introduced and became a part of everyday practice. The 
routine use of CF-sensing ablation catheters improved the arrhythmia-free survival 
after PVI. However, the recurrence rate of atrial tachyarrhythmias remained a 
substantial issue. The durability of PVI depends on the accurate lesion creation 
and contiguity of lesions. The use of high-power, short-duration radiofrequency 
applications might enable the operators to create a more uniform, more contiguous 
lesion set; therefore, a more durable PVI can be achieved. This high rate of durable 
PV isolation is expected to be associated with improved clinical outcomes for atrial 
fibrillation ablation. Clinical studies uniformly showed that PVI with high-power, 
short-duration technique is safe and effective and is associated with shorter proce-
dure and ablation times when compared with conventional low-power RF ablation. 
The long-term efficacy of very HPSD ablation is not available at the moment and 
needs to be confirmed by further trials.
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